AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Johnson & Johnson (NYSE:JNJ) researches, develops, manufactures and sells various products in the health care field worldwide ...

Q4 2024 Earnings Call Transcript January 22, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.04, ...

HistoSonics, a medical device company backed by Johnson & Johnson’s venture capital arm, is exploring the possibility of a U.S. initial ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...